NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
PL Capital Report
Anthem Biosciences Ltd. reported a weak June-quarter performance due to shipment deferments from key customers, but PL Capital remains constructive on the stock, retaining its ‘Buy' rating and target price of Rs 850 on expectations of a recovery in the coming quarters.
The brokerage said the muted Q1 FY27 performance was largely timing-related rather than demand-driven. Management indicated that shipments deferred during the quarter are expected to be recovered over the remainder of FY27, while underlying demand and order inflows remain healthy.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
